Drug Trial Radar · NCT06789445
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Mar 10, 2025
Primary completion
Oct 2029
Study completion Oct 2030
Sponsor
- Lead sponsor
- BlueRock TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Jan 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.
Conditions
- Primary Photoreceptor Disease
- Retinitis Pigmentosa (RP)
- Usher Syndrome
- Inherited Retinal Disease (IRD)
- Rod-Cone Dystrophy
- Rod-Cone Disease
- Retinal Degeneration
- Cone-Rod Disease (C-RD)
- Cone-Rod Dystrophy
Interventions
OpCT-001Biological
Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs).
OpCT-001Biological
Cell therapy product composed of photoreceptor precursor cells derived from human iPSCs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of ocular and non-ocular treatment-emergent adverse events (TEAEs) through the Week 52 visitTime frame: From OpCT-001 administration through the Week 52 visit
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California /Children's Hospital of Los Angeles
Los Angeles, California · Recruiting
University of Miami, Bascom Palmer Eye Institute
Miami, Florida · Recruiting
Mid Atlantic Retina/ Wills Eye
Philadelphia, Pennsylvania · Recruiting
Retina Foundation of the Southwest
Dallas, Texas · Recruiting
University of Wisconsin
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.